Abstract
Intranasal administration is emerging as a reliable and non-invasive method to bypass the blood–brain barrier and deliver drugs to the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. However, intranasal administration could also be used to create animal models of brain disease. Beta-amyloid peptide (Aβ) accumulation is a key feature of Alzheimer’s disease (AD), and the most common models of AD are transgenic mice expressing mutant human genes linked to familial AD. An alternative model of amyloidosis utilizes intracerebroventricular infusion of thiorphan or phosphoramidon to block the activity of key Aβ degrading enzymes (NEP, NEP2) resulting in accumulation of Aβ. Here, we demonstrate that intranasal administration of phosphoramidon produces significantly elevated cerebral Aβ levels in wild-type mice. Furthermore, intranasal phosphoramidon administration in double knockout mice lacking NEP and NEP2 also showed increased levels of Aβ40. These data show that intranasal delivery of drugs can be used to model AD and suggest that other phosphoramidon-sensitive peptidases are degrading Aβ in NEP/NEP2-deficient mice.
This is a preview of subscription content, log in via an institution to check access.
References
Carpentier M, Guillemette C, Bailey JL, Boileau G, Jeannotte L, DesGroseillers L, Charron J (2004) Reduced fertility in male mice deficient in the zinc metallopeptidase NL1. Mol Cell Biol 24:4428–4437
Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH 2nd (2009) Intranasal delivery of cells to the brain. Eur J Cell Biol 88:315–324
Dhuria SV, Hanson LR, Frey WH 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:1654–1673
Dolev I, Michaelson DM (2004) A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci USA 101:13909–13914
Hafez D, Huang JY, Huynh AM, Valtierra S, Rockenstein E, Bruno AM, Lu B, DesGroseillers L, Masliah E, Marr RA (2010) Neprilysin-2 is an important beta- amloid degrading enzyme. Am J Pathol (in press)
Hanson LR, Frey WH 2nd (2008) Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9(Suppl 3):S5
Hanson LR, Martinez PM, Taheri S, Kamsheh L, Mignot E, Frey WHI (2004) Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood–brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol 4:66–71
Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330:679–686
Huang JY, Bruno AM, Patel CA, Huynh AM, Philibert KD, Glucksman MJ, Marr RA (2008) Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40. Neuroscience 155:258–262
Ikeda K, Emoto N, Raharjo SB, Nurhantari Y, Saiki K, Yokoyama M, Matsuo M (1999) Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 274:32469–32477
Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143–150
Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292:1550–1552
Lu B, Gerard NP, Kolakowski LF Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181:2271–2275
Marr RA, Spencer BJ (2010) NEP-like endopeptidases and Alzheimer’s disease. Curr Alzheimer Res 7:223–229
Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, Noda Y, Nabeshima T (2006) Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. Behav Brain Res 168:83–91
Nisemblat Y, Belinson H, Dolev I, Michaelson DM (2007) Alzheimer’s and Parkinson’s diseases: progress and new perspectives. Abstracts of the 8th international conference AD/PD, Salzburg, Austria, March 14–18, 2007. Abstracts. Neurodegener Dis 4(Suppl 1):1–350
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hanson, L.R., Hafez, D., Svitak, A.L. et al. Intranasal Phosphoramidon Increases Beta-Amyloid Levels in Wild-Type and NEP/NEP2-Deficient Mice. J Mol Neurosci 43, 424–427 (2011). https://doi.org/10.1007/s12031-010-9460-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-010-9460-8